Oxatomide in the treatment of chronic allergic rhinitis

Fifty-six patients with chronic allergic rhinitis were selected for a randomized double-blind study comparing oxatomide with a placebo. At the end of the 1-month treatment period symptoms had disappeared or were markedly improved in 81% of the oxatomide-treated patients compared with only 17% of the placebo group. Therapeutic control was achieved in most patients with a dose of 30 mg bid. Improvements were characterized by a reduction in the number, duration and severity of episodes of rhinitis. Oxatomide also significantly reduced the requirements of patients for additional antiallergic medication. No significant side effects were reported.